Actionable trade ideas with defined risk and time horizons.
Curated trade ideas across equities, options, and other instruments, featuring clear directional bias, time horizon, and risk considerations. Trade ideas are designed to align market context, technical structure, and risk management principles.
12,275 total articles
Cadre (CDRE) looks like a tactical long: recurring demand from law enforcement and defense, a depressed share price vs. the March highs, positive cash generation and a clear path to margin improvement in H2. Entry at $30.62, target $40.00, stop $26.50; horizon: long term (180 trading days). Analysts should watch order flow, margin guidance and insi…
Nano Labs trades at a sub-$42M market cap with a P/E near 1.9 and heavy short interest. The company supplies high-performance and vision computing chips and has recent MOU activity targeting North American AI data centers. This trade idea proposes a tactical long over a mid-term horizon (45 trading days) to capture a mean-reversion rally driven by …
Archer’s July 2026 partnership with Anduril to build the autonomous Thunder VTOL gives the company a plausible near-term commercial pathway outside the slow FAA certification cycle. The market has punished Archer into a $3.7B market cap and sub-$5 share price despite meaningful cash on the balance sheet and strong headline momentum. This trade idea…
Advanced Micro Devices (AMD) sold off sharply with the rest of the chip group, leaving the stock ~25% off recent highs. The decline has pushed momentum indicators into oversold territory and trimmed valuation multiples. Given strong free cash flow, low leverage, and multi-year AI customer wins, the pullback provides a disciplined entry for a mid-te…
Centerra Gold (CGAU) looks positioned for further upside after a series of constructive corporate moves: a larger, cheaper undrawn $600M credit facility, recurring dividend, strategic equity stakes in North American exploration plays, and solid operating exposure in Canada and Türkiye. Valuation (market cap ~$3.61B, P/E ~4.9) implies the market has…
Universal Insurance Holdings has moved from crisis-era volatility to sustained profitability as underwriting and rate dynamics in Florida normalize. The balance sheet is clean, free cash flow is robust, and valuation is low relative to the earnings power the business currently demonstrates. This trade idea looks to capture further derisking and mul…
Cenovus is trading at $29.08 after a run of strength that appears tied to management commentary around materially higher free cash flow and resilient refining margins. With a market cap of $54.3B, a PE of 14.8 and a 2.18% yield, this trade bets on continued cash conversion and a re-rating toward the prior 52-week high. Entry, stop and targets are e…
NIO's delivery surge, improving margins and software/technology push make the stock a tactical buy. Market cap of ~$11.4B already prices in meaningful downside; we see a path to $7.00 over a mid-term 45 trading day trade while maintaining a disciplined stop at $4.00.
Bloom Energy’s recent commercial wins and the rapid unwind in short interest argue the company’s narrative is shifting from speculative promise to execution. The stock is volatile and richly valued, but catalysts over the next several weeks create an asymmetric trade opportunity. This idea lays out an actionable mid-term (45 trading days) long with…
Hanover has sharpened underwriting and is converting that into free cash flow and shareholder payouts. With ROE north of 20%, FCF of roughly $1.25B and a clean balance sheet, the stock can reasonably trade higher even at a modest premium to peers. This trade idea lays out an actionable long with entry, stop and target alongside the key catalysts an…
Nvidia's reported $5 billion bet on a strategic silicon initiative (SSI) is a defensive R&D and capacity move that can blunt competitor advances and extend its data‑center advantage. The market has sold the stock to $190, creating a tactical entry for investors who want exposure to Nvidia's AI moat without paying for perfection. This trade balances…
Cognizant (CTSH) has ripped more than 15% recently and today extended the move to trade near $56. The combination of healthy free cash flow ($2.47B), low leverage (debt/equity 0.04), a sub-11x P/E, and positive legal and sector headlines supports a continued re-rating. This is a tactical long with defined risk: entry $56.00, stop $49.50, target $70…
MPLX offers a compelling risk/reward after a recent pullback. The midstream operator carries a 7%+ yield, strong free cash flow and visible project-backed growth in gas and NGL services. Use a disciplined entry and stop to capture a probable Q2 reacceleration and an attractive distribution backed by solid coverage.
Alliance Resource Partners (ARLP) offers a high 9.7% yield that is largely covered by free cash flow, a modest capital structure, and bullish technical momentum. This trade plan targets income capture and a measured rally back toward 52-week highs, while protecting capital with a tight stop. Entry $25.88, target $29.00, stop $23.50. Mid-term horizo…
Match Group sits at the center of mobile dating. Strong free cash flow, attractive valuation, and product investment aimed at Gen Z create a favorable risk-reward for a long trade. Entry $39.40, first target $48.00, stop $33.00. Horizon: long term (180 trading days).
Expand Energy (EXE) looks like an actionable long after management’s announced Twin Eagle acquisition (terms pending). The deal plugs a gap in gas marketing and LNG commercialization, complements strong cash generation, and sits against a valuation that reads cheaply: market cap ~$22.2B, P/E ~6.6, EV/EBITDA ~3.6. Trade plan: enter at $92.52, stop $…
Kyverna has cleared several clinical hurdles with statistically significant registrational results in stiff person syndrome and is advancing miv-cel across other autoimmune indications. Reports of an ElevateBio manufacturing tie-up (treated here as a conditional catalyst) combined with improving commercial-readiness metrics materially de-risk near-…
Cenovus (CVE) looks positioned to convert elevated commodity prices into cash that flows to the bottom line. With Q2 results and a bullish technical backdrop, the stock offers a defined risk-reward swing: enter at $29.06, stop $26.50, target $33.50 over a mid-term 45 trading day window.
Nvidia remains the clear leader in AI accelerators and data-center GPUs. Recent pullbacks have trimmed momentum but not the structural drivers: >80% share in AI data-center GPUs, massive free cash flow, and continued product expansion into CPUs and networking. I outline a tactical long trade with a clear entry, stop and target and explain the catal…
Coherus Oncology ($CHRS) is a low-priced, catalyst-rich microcap trading at roughly $1.44 with a market cap near $227M. Management has recently raised ~$50M, advanced a Phase 1 collaboration for LOQTORZI combinations, and set an earnings call for 08/05/2026. Given the cash infusion, a lighter enterprise value (~$144M), and heavy short interest, the…
Bandwidth (BAND) gapped sharply from $52.25 to the $38 area and is trading oversold with RSI ~28. The combination of meaningful free cash flow ($79.4M), enterprise adoption commentary, attractive EV/Sales (~2.3) and a large end-market tailwind for CPaaS argues for buying this dip. Enter at $37.80 with a $33 stop and a $52 target on a mid-term (45 t…
Micron plunged in late July on macro and geopolitical fear, but fundamentals tied to AI data-center memory demand remain supportive. The setup offers a defined-risk entry with upside to prior highs if pricing and capacity tightness persist.
SK hynix is deeply exposed to the AI-driven memory squeeze that has lifted chipmakers' profits. The stock has pulled back sharply from its highs; this trade idea outlines an actionable long with a clear entry at $127.00, a stop at $119.00 and a first target at $165.00 over a mid-term horizon (45 trading days). The plan leans on recent earnings stre…
<p>BillionToOne (BTO) is a clinical genomics company with a credible long-term story around non-invasive genetic testing, but near-term guidance and commercialization pace appear conservative while the equity looks priced for a faster ramp. That divergence creates a defined-reward short opportunity for disciplined traders willing to carry execution…
Electrovaya (ELVA) has been knocked around this year, but two facts have changed the risk-reward for me: a financed plan to secure manufacturing capacity and improving short interest dynamics. I’m doubling my target to $15.40 and taking a long position with a clear stop and a 180-trading-day horizon. This is a high-conviction, high-volatility trade…
